BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27166254)

  • 21. Reduction of transforming growth factor-beta type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinoma.
    Fukasawa H; Yamamoto T; Fujigaki Y; Misaki T; Ohashi N; Takayama T; Suzuki S; Mugiya S; Oda T; Uchida C; Kitagawa K; Hattori T; Hayashi H; Ozono S; Kitagawa M; Hishida A
    Int J Cancer; 2010 Oct; 127(7):1517-25. PubMed ID: 20073064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Smad2/Smad3 in endothelium is indispensable for vascular stability via S1PR1 and N-cadherin expressions.
    Itoh F; Itoh S; Adachi T; Ichikawa K; Matsumura Y; Takagi T; Festing M; Watanabe T; Weinstein M; Karlsson S; Kato M
    Blood; 2012 May; 119(22):5320-8. PubMed ID: 22498737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors.
    Goumans MJ; Valdimarsdottir G; Itoh S; Rosendahl A; Sideras P; ten Dijke P
    EMBO J; 2002 Apr; 21(7):1743-53. PubMed ID: 11927558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.
    Sugano Y; Matsuzaki K; Tahashi Y; Furukawa F; Mori S; Yamagata H; Yoshida K; Matsushita M; Nishizawa M; Fujisawa J; Inoue K
    Oncogene; 2003 Apr; 22(15):2309-21. PubMed ID: 12700666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. c-Ski accelerates renal cancer progression by attenuating transforming growth factor β signaling.
    Taguchi L; Miyakuni K; Morishita Y; Morikawa T; Fukayama M; Miyazono K; Ehata S
    Cancer Sci; 2019 Jun; 110(6):2063-2074. PubMed ID: 30972853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased TGFBR3/betaglycan expression enhances the metastatic abilities of renal cell carcinoma cells through TGF-β-dependent and -independent mechanisms.
    Nishida J; Miyazono K; Ehata S
    Oncogene; 2018 Apr; 37(16):2197-2212. PubMed ID: 29391598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of ALK5/Smad2/3 and MEK1/ERK Signaling in Transforming Growth Factor Beta 1-modulated Growth, Collagen Turnover, and Differentiation of Stem Cells from Apical Papilla of Human Tooth.
    Chang HH; Chang MC; Wu IH; Huang GF; Huang WL; Wang YL; Lee SY; Yeh CY; Guo MK; Chan CP; Hsien HC; Jeng JH
    J Endod; 2015 Aug; 41(8):1272-80. PubMed ID: 26001858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action.
    Bartscht T; Rosien B; Rades D; Kaufmann R; Biersack H; Lehnert H; Gieseler F; Ungefroren H
    Mol Cancer; 2015 Nov; 14():199. PubMed ID: 26588899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caveolin-2 is a negative regulator of anti-proliferative function and signaling of transforming growth factor-β in endothelial cells.
    Xie L; Vo-Ransdell C; Abel B; Willoughby C; Jang S; Sowa G
    Am J Physiol Cell Physiol; 2011 Nov; 301(5):C1161-74. PubMed ID: 21832243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression and function of alternative splice variants of the mouse TGF-beta type I receptor.
    Murakami M; Kondo S; Funaba M
    Cell Biol Int; 2008 Jul; 32(7):848-54. PubMed ID: 18474439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increase in ALK1/ALK5 ratio as a cause for elevated MMP-13 expression in osteoarthritis in humans and mice.
    Blaney Davidson EN; Remst DF; Vitters EL; van Beuningen HM; Blom AB; Goumans MJ; van den Berg WB; van der Kraan PM
    J Immunol; 2009 Jun; 182(12):7937-45. PubMed ID: 19494318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis.
    de Gouville AC; Boullay V; Krysa G; Pilot J; Brusq JM; Loriolle F; Gauthier JM; Papworth SA; Laroze A; Gellibert F; Huet S
    Br J Pharmacol; 2005 May; 145(2):166-77. PubMed ID: 15723089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RAP250 is a coactivator in the transforming growth factor beta signaling pathway that interacts with Smad2 and Smad3.
    Antonson P; Jakobsson T; Almlöf T; Guldevall K; Steffensen KR; Gustafsson JA
    J Biol Chem; 2008 Apr; 283(14):8995-9001. PubMed ID: 18263591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transforming growth factor-beta pathway in human renal cell carcinoma and surrounding normal-appearing renal parenchyma.
    Cardillo MR; Lazzereschi D; Gandini O; Di Silverio F; Colletta G
    Anal Quant Cytol Histol; 2001 Apr; 23(2):109-17. PubMed ID: 11332076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TGF-β1/ALK5-induced monocyte migration involves PI3K and p38 pathways and is not negatively affected by diabetes mellitus.
    Olieslagers S; Pardali E; Tchaikovski V; ten Dijke P; Waltenberger J
    Cardiovasc Res; 2011 Aug; 91(3):510-8. PubMed ID: 21478266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BIGH3 is overexpressed in clear cell renal cell carcinoma.
    Yamanaka M; Kimura F; Kagata Y; Kondoh N; Asano T; Yamamoto M; Hayakawa M
    Oncol Rep; 2008 Apr; 19(4):865-74. PubMed ID: 18357369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced expression of growth and differentiation factor-9 (GDF9) is associated with aggressive behaviour of human clear-cell renal cell carcinoma and poor patient survival.
    Du P; Ye L; Yang Y; Jiang WG
    Anticancer Res; 2014 Nov; 34(11):6515-20. PubMed ID: 25368253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
    Grygielko ET; Martin WM; Tweed C; Thornton P; Harling J; Brooks DP; Laping NJ
    J Pharmacol Exp Ther; 2005 Jun; 313(3):943-51. PubMed ID: 15769863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.